The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FOLD | -27.97% | -53.73% | -14.29% | -41% |
| S&P | +14.5% | +93.32% | +14.09% | +338% |
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Investors cheered an analyst's upgrade of the biotech stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $154.69M | 22.1% |
| Gross Profit | $137.62M | 21.5% |
| Gross Margin | 88.97% | -0.4% |
| Market Cap | $1.76B | -40.0% |
| Market Cap / Employee | $3.54M | 0.0% |
| Employees | 499 | -3.5% |
| Net Income | -$24.42M | -55.6% |
| EBITDA | -$5.92M | -134.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $158.70M | -24.2% |
| Accounts Receivable | $105.85M | 24.3% |
| Inventory | 154.9 | 90.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $434.71M | -0.3% |
| Short Term Debt | $8.61M | 6.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.87% | 11.3% |
| Return On Invested Capital | -29.66% | 8.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$28.93M | -234.0% |
| Operating Free Cash Flow | -$26.53M | -216.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.84 | 15.73 | 12.58 | 9.12 | -59.45% |
| Price to Sales | 6.59 | 5.33 | 4.62 | 3.09 | -53.24% |
| Price to Tangible Book Value | -86.22 | -76.05 | -116.48 | -85.53 | 152.64% |
| Price to Free Cash Flow TTM | 1561.41 | - | |||
| Enterprise Value to EBITDA | 127.87 | 167.15 | -442.13 | -334.23 | -279.26% |
| Free Cash Flow Yield | 0.1% | - | |||
| Return on Equity | -67.1% | -31.7% | -18.1% | -22.6% | -76.90% |
| Total Debt | $444.66M | $443.64M | $443.47M | $443.32M | -0.17% |
FOLD earnings call for the period ending September 30, 2021.
FOLD earnings call for the period ending June 30, 2021.
FOLD earnings call for the period ending March 31, 2021.
FOLD earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
